image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Media Contact:
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
Lwolffe@wheelhouselsa.com

Date Title and Summary Additional Format
August 3, 2022 Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer
SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Eric Schlezinger, J.D. has joined the company as chief people officer. Mr.
PDF Version
July 8, 2022 Nurix Therapeutics Announces $40 Million Registered Direct Offering
SAN FRANCISCO, July 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with two healthcare-focused investment funds to
PDF Version
July 7, 2022 Nurix Therapeutics Announces $55 Million Registered Direct Offering
SAN FRANCISCO, July 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with an institutional investor to sell, in a
PDF Version
July 7, 2022 Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update
NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial First patient dosed in NX-5948 Phase 1a clinical trial for certain B-cell malignancies NX-1607 IND cleared FDA for expansion of enrollment to U.S. clinical sites for patients with solid tumors Research engine
PDF Version
June 30, 2022 Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types Phase 1 clinical trial now enrolling patients in U.K. with plans to expand to clinical sites in the U.S. SAN FRANCISCO, June 30, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.
PDF Version
June 10, 2022 Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress
Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127 and NX-5948 programs SAN FRANCISCO, June 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein
PDF Version
June 3, 2022 Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127, DeTIL-0255, and NX-1607 programs SAN FRANCISCO, June 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.   (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted
PDF Version
May 26, 2022 Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development
Data to be discussed at Nurix R&D Day at 8:00 a.m. ET today May 26 SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has initiated the first of several potential
PDF Version
May 17, 2022 Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas
Company delivers on ambitious clinical development goal with four ongoing clinical trials in 2022 SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that
PDF Version
May 11, 2022 Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 11, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.   (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a
PDF Version
Displaying 11 - 20 of 32
Print Page
Email Alerts
RSS Feeds
Contact IR